Mavatar Delivers New Data-Driven Resources to Advance Precision Medicine for IBD
Mavatar, a global specialist in AI and data-driven precision medicine solutions, announces a key milestone in its contribution to the national project “Precision Medicine in Inflammatory Bowel Disease (IBD)”, funded by Vinnova. The company has developed an integrated transcriptomic resource designed to support a broad range of studies within precision medicine for patients with IBD.
The initiative, led by RISE and involving a broad consortium of academic, clinical, and industry partners, aims to improve diagnosis, treatment, and long-term outcomes for the more than 85,000 people living with IBD in Sweden.
As part of the project, Mavatar has delivered a high-quality, integrated data resource designed to accelerate precision medicine research across Crohn’s disease and ulcerative colitis, two of the most complex and burdensome chronic conditions in the gastrointestinal field.
Dr. Ann-Sofie Backman, Associate Professor at Karolinska Institutet and Senior Consultant in the Gastroenterology Unit at Ersta Hospital.
“This collaboration demonstrates the value of combining clinical expertise with structured, data-driven resources. It’s encouraging to see how these tools are already informing research and opening new possibilities for more precise and effective IBD care.”
New Foundation for IBD Precision Medicine
Using its AI- and data-driven analysis platform, Mavatar has developed:
- A comprehensive integrated transcriptomic database for IBD, encompassing peer-reviewed datasets across tissues, disease stages and patient populations.
- Disease-specific biological networks, for Crohn’s disease and ulcerative colitis, providing structured insight into genes and pathway interactions in each condition.
- Identified gene modules—novel sets of functionally related genes in IBDs, and their correlations with disease activity, inflammation and other biological processes relevant to inflammation and treatment response.
These deliverables were created in close collaboration with project partners and will support the development of tools for predictive diagnostics and individualized treatment strategies.
A National Collaboration for Smarter IBD Care
The broader project includes partners such as Lund University, Örebro University, Ersta Hospital, Region Skåne, Region Östergötland, Innovation Skåne, Pfizer, Takeda, and Mavatar.
“Working with our partners has been essential,” says Fredrik Barrenäs, CTO and Co-founder of Mavatar.
“Computational biology is only as powerful as your understanding of the disease area. Given the complexity of IBD, close collaboration with clinical and biomedical experts is what enables us to turn advanced models into real-world insights.”
Next Steps: From Insight to Impact
Mavatar’s contributions will now be used in ongoing work packages to:
- Identify molecular subtypes of IBD
- Explore predictors of treatment response
- Support the long-term goal of personalized therapy selection in clinical settings
These resources form an essential building block toward precision-medicine approaches in IBD, making smarter, more personalized care a reality for patients.
For more information contact:
Linda Wakeham
Chief Marketing and Communication Officer
linda.wakeham@mavatar.com
Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered in Stockholm, Sweden, Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas.
Tags:
